JP7862331B2 - GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 - Google Patents

GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用

Info

Publication number
JP7862331B2
JP7862331B2 JP2022580238A JP2022580238A JP7862331B2 JP 7862331 B2 JP7862331 B2 JP 7862331B2 JP 2022580238 A JP2022580238 A JP 2022580238A JP 2022580238 A JP2022580238 A JP 2022580238A JP 7862331 B2 JP7862331 B2 JP 7862331B2
Authority
JP
Japan
Prior art keywords
xyl
rha
fuc
saponin
glc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022580238A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533693A5 (cg-RX-API-DMAC10.html
JP2023533693A (ja
Inventor
ポステル,ルーベン
ヘアマンス,ガイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapreme Technologies BV
Original Assignee
Sapreme Technologies BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Application filed by Sapreme Technologies BV filed Critical Sapreme Technologies BV
Priority claimed from PCT/NL2021/050394 external-priority patent/WO2021261998A1/en
Publication of JP2023533693A publication Critical patent/JP2023533693A/ja
Publication of JP2023533693A5 publication Critical patent/JP2023533693A5/ja
Priority to JP2026073994A priority Critical patent/JP2026126321A/ja
Application granted granted Critical
Publication of JP7862331B2 publication Critical patent/JP7862331B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022580238A 2020-06-24 2021-06-23 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 Active JP7862331B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026073994A JP2026126321A (ja) 2020-06-24 2026-04-27 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2025902 2020-06-24
NL2025902 2020-06-24
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
NLPCT/NL2021/050384 2021-06-18
PCT/NL2021/050394 WO2021261998A1 (en) 2020-06-24 2021-06-23 Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026073994A Division JP2026126321A (ja) 2020-06-24 2026-04-27 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用

Publications (3)

Publication Number Publication Date
JP2023533693A JP2023533693A (ja) 2023-08-04
JP2023533693A5 JP2023533693A5 (cg-RX-API-DMAC10.html) 2024-07-01
JP7862331B2 true JP7862331B2 (ja) 2026-05-19

Family

ID=72087123

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580238A Active JP7862331B2 (ja) 2020-06-24 2021-06-23 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用
JP2026073994A Pending JP2026126321A (ja) 2020-06-24 2026-04-27 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026073994A Pending JP2026126321A (ja) 2020-06-24 2026-04-27 GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用

Country Status (6)

Country Link
US (1) US20230293562A1 (cg-RX-API-DMAC10.html)
EP (2) EP4596052A3 (cg-RX-API-DMAC10.html)
JP (2) JP7862331B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230044196A (cg-RX-API-DMAC10.html)
CN (1) CN116194148A (cg-RX-API-DMAC10.html)
IL (1) IL299349A (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060043A1 (en) * 2024-09-10 2026-03-19 Xact Bio, Inc. Compositions and methods for targeting a tissue specific protein expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071388A1 (en) 2013-11-14 2015-05-21 Roche Innovation Center Copenhagen A/S Apob antisense conjugate compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522213A1 (en) * 2003-04-08 2004-10-28 Dante J. Marciani Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071388A1 (en) 2013-11-14 2015-05-21 Roche Innovation Center Copenhagen A/S Apob antisense conjugate compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomedicines,2017年,Vol.5, No.14,pp.1-25
Molecular Therapy: Nucleic acids,2019年,Vol.14,pp. 67-79

Also Published As

Publication number Publication date
EP4596052A2 (en) 2025-08-06
EP4596052A3 (en) 2025-11-05
EP4171643C0 (en) 2025-06-04
JP2026126321A (ja) 2026-08-04
EP4171643A1 (en) 2023-05-03
US20230293562A1 (en) 2023-09-21
KR20230044196A (ko) 2023-04-03
JP2023533693A (ja) 2023-08-04
IL299349A (en) 2023-02-01
EP4171643B1 (en) 2025-06-04
CN116194148A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
EP4171641B1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
JP2024530839A (ja) サポニン、オリゴヌクレオチド、およびGalNAcの複合体
WO2021261998A1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
JP2011500002A (ja) Rna干渉効果が高い脂質修飾2本鎖rna
EP4171643B1 (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
EP4210760B1 (en) Conjugate of saponin, oligonucleotide and galnac
AU2021295358B2 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40128805A (en) Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof
HK40116734A (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate
HK40129944A (zh) Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物
HK40124033A (en) Conjugate of saponin, oligonucleotide and galnac
CN117881427A (zh) 皂苷、寡核苷酸和galnac的缀合物
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
AU2021339332A1 (en) Conjugate of saponin, oligonucleotide and GalNAc

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260507

R150 Certificate of patent or registration of utility model

Ref document number: 7862331

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150